NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack ID2689

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
AstraZeneca (ticagrelor)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Anticoagulation UK	Board of Community Health Councils in
Blood Pressure UK	Wales
British Cardiac Patients Association	British National Formulary
Cardiovascular Care Partnership	Care Quality Commission
Different Strokes	Department of Health, Social Services
HEART UK	and Public Safety for Northern Ireland
Muslim Council of Britain	Healthcare Improvement Scotland
Network of Sikh Organisations	Medicines and Healthcare products
Neurological Alliance	Regulatory Agency
Pumping Marvellous	National Association of Primary Care
Somerville Foundation	National Pharmacy Association
South Asian Health Foundation	Neurological Alliance of Scotland
Specialised Healthcare Alliance	NHS Alliance
Stroke Association	NHS Confederation
Stroke Information	Scottish Medicines Consortium
Thrombosis UK	Wales Neurological Alliance
	Welsh Health Specialised Services Operation
Professional groups	Committee
Association of British Neurologists Different Alberta Market Consists	Possible comparator companies
British and Irish Hypertension Society Dritish Association for Number 1:	Possible comparator companiesAccord UK (aspirin, clopidogrel,
British Association for Nursing in Cardiavascular Care	modified-release dipyridamole)
Cardiovascular Care	Advanz Pharma (modified-release
British Association of Stroke Physicians	dipyridamole)
British Cardiovascular Intervention	Alliance Pharmaceuticals (aspirin)
Society	Aspire Pharma (clopidogrel)
British Cardiovascular Society	Aurobindo Pharma – Milpharm
British Geriatrics Society	(clopidogrel)
British Heart Foundation	The Boots Company (aspirin)
British Heart Rhythm Society	Consilient Health (clopidogrel)
British Institute of Radiology	Dexcel Pharma (aspirin)
<u> </u>	Dr Reddy's Laboratories (modified-

Provisional stakeholder list for the technology appraisal of ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack ID2689 Issue date: June 2020 © National Institute for Health and Care Excellence 2020. All rights reserved Page 1 of 4

Consultees Commentators (no right to submit or appeal) release dipyridamole, modified-release **British Neuropathological Society** dipyridamole with aspirin) **British Orthopaedic Association** Healthcare Pharma (aspirin) British Society for Haematology Intrapharm Laboratories (aspirin) British Society for Haemostasis and Kent Pharmaceuticals (clopidogrel) **Thrombosis** M&A Pharmachem (aspirin) British Society for Heart Failure British Society of Cardiovascular Mylan (clopidogrel) Sanofi (clopidogrel) **Imaging** British Society of Rehabilitation Zentiva (clopidogrel) Medicine **British Thoracic Society** Relevant research groups British Society for Cardiovascular **British Vein Institute** Research Clinical Leaders of Thrombosis • Cochrane Heart Group Institute of Neurology Cochrane Stroke Group Primary Care Neurology Society European Council for Cardiovascular Royal College of Emergency Medicine Research Royal College of General Practitioners Health Research Authority Royal College of Nursing MRC Clinical Trials Unit Royal College of Pathologists National Hospital for Neurology and Royal College of Physicians Neurosurgery Royal College of Radiologists National Institute for Health Research Royal Pharmaceutical Society Society for Research in Rehabilitation Royal Society of Medicine Wellcome Trust Society and College of Radiographers Society for Cardiological Science & Associated Public Health groups Technology Public Health England Society for Vascular Technology Public Health Wales Society of Vascular Nurses **UK Clinical Pharmacy Association** Vascular Society of Great Britain and Ireland Others Department of Health and Social Care NHS England NHS Hammersmith and Fulham CCG NHS North Manchester CCG Welsh Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations

Provisional stakeholder list for the technology appraisal of ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack ID2689 Issue date: June 2020 © National Institute for Health and Care Excellence 2020. All rights reserved Page 2 of 4

from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Provisional stakeholder list for the technology appraisal of ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack ID2689 Issue date: June 2020 © National Institute for Health and Care Excellence 2020. All rights reserved Page 4 of 4

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.